| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/26/2006 | US7112412 Binding to prostate specific membrane antigen (PSMA) with a radioactive monoclonal antibody or Fab fragments; detecting and kill the cancer cells; bioassay; radiotherapy |
| 09/26/2006 | US7112409 Bioassay of measuring tyrosine-kinase ligand, tumor necrosis factor and transforming growth factor level, before administering the myelosuppressive agent to the patient; use in optimizing treatment and avoiding toxic effects |
| 09/26/2006 | US7112405 Compositions and methods for enhancing oligonucleotide-mediated gene alteration |
| 09/26/2006 | US7112342 Enriched platelet wound healant |
| 09/26/2006 | US7112341 stabilized follicle stimulating protein (FSP), follicle-stimulating hormone (FSH), dry powder compositions for aerosolized delivery to the deep lung |
| 09/26/2006 | US7112333 T cell epitopes of ryegrass pollen allergen |
| 09/26/2006 | US7112329 useful in peptide-based immunotherapy for patients with spring tree pollinosis; diagnosis; |
| 09/26/2006 | US7112328 Composition for targeted cell treatment |
| 09/26/2006 | US7112326 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/26/2006 | US7112325 Antibodies to calcium independent cytosolic phospholipase A2/B enzymes |
| 09/26/2006 | US7112324 CD 19×CD3 specific polypeptides and uses thereof |
| 09/26/2006 | US7112320 Solid wound healing formulations containing fibronectin |
| 09/26/2006 | US7112317 Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker. |
| 09/26/2006 | CA2283464C Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 09/26/2006 | CA2254953C Therapies for chronic renal failure |
| 09/24/2006 | CA2539281A1 Methods for the treatment of insulin resistance and disease states characterized by insulin resistance |
| 09/24/2006 | CA2516364A1 Method of modulation |
| 09/21/2006 | WO2006099539A1 Reg iv: a target for cancer diagnosis and therapy |
| 09/21/2006 | WO2006099480A2 Stress proteins and peptides and methods of use thereof |
| 09/21/2006 | WO2006099309A2 Keratin and soluble derivatives thereof for treating oxidative stress and inflammation and promoting skin health |
| 09/21/2006 | WO2006099288A2 Controlled release formulations of octreotide |
| 09/21/2006 | WO2006099261A2 Potent and specific immunoproteasome inhibitors |
| 09/21/2006 | WO2006099154A1 Treating anemia by inhibition of vegf |
| 09/21/2006 | WO2006098764A2 Potassium channel blockers |
| 09/21/2006 | WO2006098625A1 Dermatologic use of milk proteins |
| 09/21/2006 | WO2006098524A1 Prophylactic/therapeutic agent for stress-induced bowel disease |
| 09/21/2006 | WO2006098488A1 Method of ameliorating symptom caused by mood disturbance |
| 09/21/2006 | WO2006098463A1 Polynucleic acid-binding substance |
| 09/21/2006 | WO2006098422A1 Anti-alopecia agent using super anti-apoptotic protein fnk |
| 09/21/2006 | WO2006098304A1 Novel secretory protein derived from pituitary cell and use of the same |
| 09/21/2006 | WO2006098074A1 Apoptosis inducing agent for prostate carcinoma cell |
| 09/21/2006 | WO2006097854A1 Heterodimeric meganucleases and use thereof |
| 09/21/2006 | WO2006097793A2 Compositions capable of facilitating penetration across a biological barrier |
| 09/21/2006 | WO2006097732A2 Treatment of autoimmune and inflammatory diseases |
| 09/21/2006 | WO2006097682A1 Mechano growth factor peptides and their use |
| 09/21/2006 | WO2006097538A1 Extended glp-1 compounds |
| 09/21/2006 | WO2006097537A2 Acylated glp-1 compounds |
| 09/21/2006 | WO2006097536A2 Dimeric peptide agonists of the glp-1 receptor |
| 09/21/2006 | WO2006097526A1 Compounds for use in the treatment of obesity |
| 09/21/2006 | WO2006097462A2 Compositions and methods for treating inflammatory cns disorders |
| 09/21/2006 | WO2006097416A1 Compounds for use in the prevention and treatment of alzheimer's disease |
| 09/21/2006 | WO2006097335A1 A new element of the wg/wnt signaling pathway |
| 09/21/2006 | WO2006097327A2 Soluble btnl2 protein useful to inhibit inflammatory disorders |
| 09/21/2006 | WO2006097110A2 Polypeptides having antimicrobial activity and polynucleotides encoding same |
| 09/21/2006 | WO2006096953A1 Use of crotamine, kit and composition |
| 09/21/2006 | WO2006096931A1 Renal repair and regeneration |
| 09/21/2006 | WO2006084141A3 Suspension formulation of interferon |
| 09/21/2006 | WO2006076453A3 METHOD FOR DELIVERING INTERFERON-β |
| 09/21/2006 | WO2006055806A3 Diagnostic, prognostic, and therapeutic factor smac/diablo in human cancer |
| 09/21/2006 | WO2006046951A3 Cell cycle arrest and apoptosis |
| 09/21/2006 | WO2006046734A3 Novel aminopyridine derivatives having selective aurora-a inhibitory effect |
| 09/21/2006 | WO2006045037A3 Truncated fragments of alpha-synuclein in lewy body disease |
| 09/21/2006 | WO2006042848A3 Growth hormone conjugates |
| 09/21/2006 | WO2006031811A3 Glycopegylated interferon alpha |
| 09/21/2006 | WO2006031267A3 Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| 09/21/2006 | WO2006028897A3 Liquefaction and saccharifaction processes |
| 09/21/2006 | WO2006019894A3 Nebulized pharmaceutical compositions for the treatment of bronchial disorders |
| 09/21/2006 | WO2006007412A9 Peptide yy formulations having increased stability and resistance to microbial agents |
| 09/21/2006 | WO2005112988B1 Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1) |
| 09/21/2006 | WO2005090395A3 Methods for increasing protein polyethylene glycol (peg) conjugation |
| 09/21/2006 | WO2005089229A3 Vpac1 selective antagonists and their pharmacological methods of use |
| 09/21/2006 | WO2005077105A3 Reduction of hiv-1 replication by a mutant apolipoprotein b mrna editing enzyme-catalytic polypeptide-like 3 g (apobec3g) |
| 09/21/2006 | WO2005058236A8 Cab molecules |
| 09/21/2006 | WO2005032474A3 Pharmaceutical compositions for prevention of overdose or abuse |
| 09/21/2006 | WO2005001057A3 Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof |
| 09/21/2006 | WO2002050303A3 Protein-protein interactions |
| 09/21/2006 | US20060212959 Transposase and method of gene modification |
| 09/21/2006 | US20060212958 cis-element of Oryzias Latipes Tol2 element (inverted terminal repeat sequences); plasmids |
| 09/21/2006 | US20060212950 Inducible small rna expression constructs for targeted gene silencing |
| 09/21/2006 | US20060212109 Delivery of therapeutic capable agents |
| 09/21/2006 | US20060212077 Electromagnetic treatment apparatus for augmenting wound repair and method for using same |
| 09/21/2006 | US20060211848 Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses |
| 09/21/2006 | US20060211768 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| 09/21/2006 | US20060211659 Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof |
| 09/21/2006 | US20060211640 Antisense modulation of farnesoid X receptor expression |
| 09/21/2006 | US20060211639 Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| 09/21/2006 | US20060211630 Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders |
| 09/21/2006 | US20060211629 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 09/21/2006 | US20060211628 Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| 09/21/2006 | US20060211627 Methods and compositions for derepression of IAP-inhibited caspase |
| 09/21/2006 | US20060211626 For treating preterm labor and dysmenorrhea |
| 09/21/2006 | US20060211625 New hybrid oligomers, their preparation process and pharmaceutical compositions containing them |
| 09/21/2006 | US20060211624 Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies |
| 09/21/2006 | US20060211623 Conopeptides |
| 09/21/2006 | US20060211622 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof |
| 09/21/2006 | US20060211621 Combined use of factor VII polypeptides and factor IX polypeptides |
| 09/21/2006 | US20060211620 Nucleic acid constructs, recombinant expression vectors, and recombinant host cells comprising the polynucleotides |
| 09/21/2006 | US20060211619 Polypeptide having endopeptidase domain;translocation domain having more than one binding domain directed to a cell surface feature of a target cell; modified neurotoxins; to prevent exocytosis and secretion by the target cell; disorders of tsensory or motor nervous system, acute or chronic pain, cancer |
| 09/21/2006 | US20060211618 Polynucleotides and polypeptides of the erythropoietin gene |
| 09/21/2006 | US20060211617 Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| 09/21/2006 | US20060211615 Surfactant peptide nanostructures, and uses thereof |
| 09/21/2006 | US20060211614 Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1 |
| 09/21/2006 | US20060211613 Administering parathyroid hormone and bone resorption inhibitor; bone disorders |
| 09/21/2006 | US20060211612 Angiogenesis using hepatocyte growth factor |
| 09/21/2006 | US20060211610 Controlling biological activities such as cell proliferation, nutrient transport, lipolysis and intestinal water and electrolyte secretion; PYY agonists: obesity, antidiabetic agents, eating disorders; cardiovascular diseasse; PYY antagonist: facilitating weight gain and appetite increase |
| 09/21/2006 | US20060211609 Novel agent for improving neurotransmission failure |
| 09/21/2006 | US20060211608 Use of a parathyroid hormone peptide analogs for the treatment of viginal atrophy |
| 09/21/2006 | US20060211607 Somatostatin-dopamine chimeric analogs |
| 09/21/2006 | US20060211606 Peptides |
| 09/21/2006 | US20060211605 Mucosal repair by TFF dimer peptides |